These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 29196725)
41. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. Baker TB; Piper ME; Stein JH; Smith SS; Bolt DM; Fraser DL; Fiore MC JAMA; 2016 Jan; 315(4):371-9. PubMed ID: 26813210 [TBL] [Abstract][Full Text] [Related]
42. Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. Chen LS; Baker TB; Piper ME; Smith SS; Gu C; Grucza RA; Smith GD; Munafo M; Bierut LJ Drug Alcohol Depend; 2014 Oct; 143():36-43. PubMed ID: 25073833 [TBL] [Abstract][Full Text] [Related]
43. In vitro and ex vivo analysis of CHRNA3 and CHRNA5 haplotype expression. Doyle GA; Wang MJ; Chou AD; Oleynick JU; Arnold SE; Buono RJ; Ferraro TN; Berrettini WH PLoS One; 2011; 6(8):e23373. PubMed ID: 21858091 [TBL] [Abstract][Full Text] [Related]
44. Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. Chen LS; Baker TB; Piper ME; Breslau N; Cannon DS; Doheny KF; Gogarten SM; Johnson EO; Saccone NL; Wang JC; Weiss RB; Goate AM; Bierut LJ Am J Psychiatry; 2012 Jul; 169(7):735-42. PubMed ID: 22648373 [TBL] [Abstract][Full Text] [Related]
45. From men to mice: CHRNA5/CHRNA3, smoking behavior and disease. Ware JJ; van den Bree M; Munafò MR Nicotine Tob Res; 2012 Nov; 14(11):1291-9. PubMed ID: 22544838 [TBL] [Abstract][Full Text] [Related]
46. Implications of gene-drug interactions in smoking cessation for improving the prevention of chronic degenerative diseases. Quaak M; van Schayck CP; Knaapen AM; van Schooten FJ Mutat Res; 2009 Jul; 667(1-2):44-57. PubMed ID: 19028511 [TBL] [Abstract][Full Text] [Related]
47. Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Chen X; Chen J; Williamson VS; An SS; Hettema JM; Aggen SH; Neale MC; Kendler KS Am J Med Genet B Neuropsychiatr Genet; 2009 Oct; 150B(7):926-33. PubMed ID: 19132693 [TBL] [Abstract][Full Text] [Related]
48. SNPs within CHRNA5-A3-B4 and CYP2A6/B6 are associated with smoking dependence but not with tobacco dependence treatment outcomes in the Czech population. Hubacek JA; Pankova A; Stepankova L; Zvolska K; Adamkova V; Lanska V; Kralikova E Gene; 2017 Mar; 606():35-38. PubMed ID: 28069549 [TBL] [Abstract][Full Text] [Related]
51. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Falcone M; Jepson C; Benowitz N; Bergen AW; Pinto A; Wileyto EP; Baldwin D; Tyndale RF; Lerman C; Ray R Nicotine Tob Res; 2011 Jun; 13(6):498-503. PubMed ID: 21385908 [TBL] [Abstract][Full Text] [Related]
52. Predictors of treatment success in smoking cessation with varenicline combined with nicotine replacement therapy v. varenicline alone. Noor F; Koegelenberg CFN; Esterhuizen TM; Irusen EM S Afr Med J; 2017 Dec; 108(1):45-49. PubMed ID: 29262978 [TBL] [Abstract][Full Text] [Related]
53. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Zhu AZ; Zhou Q; Cox LS; David SP; Ahluwalia JS; Benowitz NL; Tyndale RF Clin Pharmacol Ther; 2014 Aug; 96(2):256-65. PubMed ID: 24733007 [TBL] [Abstract][Full Text] [Related]
54. SNPs within CHRNA5-A3-B4 and CYP2A6/B6, nicotine metabolite concentrations and nicotine dependence treatment success in smokers. Hubacek JA; Kurcova I; Maresova V; Pankova A; Stepankova L; Zvolska K; Lanska V; Kralikova E Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Mar; 165(1):84-89. PubMed ID: 31796940 [TBL] [Abstract][Full Text] [Related]
55. Association of CHRNA4 polymorphisms with smoking behavior in two populations. Han S; Yang BZ; Kranzler HR; Oslin D; Anton R; Gelernter J Am J Med Genet B Neuropsychiatr Genet; 2011 Jun; 156B(4):421-9. PubMed ID: 21445957 [TBL] [Abstract][Full Text] [Related]
56. Nicotinic α5 receptor subunit mRNA expression is associated with distant 5' upstream polymorphisms. Smith RM; Alachkar H; Papp AC; Wang D; Mash DC; Wang JC; Bierut LJ; Sadee W Eur J Hum Genet; 2011 Jan; 19(1):76-83. PubMed ID: 20700147 [TBL] [Abstract][Full Text] [Related]
57. Pathways to precision medicine in smoking cessation treatments. Chen LS; Horton A; Bierut L Neurosci Lett; 2018 Mar; 669():83-92. PubMed ID: 27208830 [TBL] [Abstract][Full Text] [Related]
58. Dissection of the phenotypic and genotypic associations with nicotinic dependence. Chen LS; Baker TB; Grucza R; Wang JC; Johnson EO; Breslau N; Hatsukami D; Smith SS; Saccone N; Saccone S; Rice JP; Goate AM; Bierut LJ Nicotine Tob Res; 2012 Apr; 14(4):425-33. PubMed ID: 22102629 [TBL] [Abstract][Full Text] [Related]
59. From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Salloum NC; Buchalter ELF; Chanani S; Espejo G; Ismail MS; Laine RO; Nageeb M; Srivastava AB; Trapp N; Trillo L; Vance E; Wenzinger M; Hartz SM; David SP; Chen LS Pharmacogenomics; 2018 Jul; 19(10):861-871. PubMed ID: 29914292 [TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece. Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]